NASDAQ:ILMN

Illumina Stock Forecast, Price & News

$191.04

+6.68 (+3.62%)

(As of 07/1/2022 05:43 PM ET)

Add

Compare

Today's Range: $183.19
▼
$191.33
50-Day Range: $181.58
▼
$319.10
52-Week Range: $180.00
▼
$526.00

Volume: 1.12 million shs
Average Volume: 1.79 million shs
Market Capitalization: $30.01 billion

P/E Ratio: 41.53
Dividend Yield: N/A
Price Target: $425.09

Illumina MarketRank™ Forecast

Analyst Rating: Hold
2.33 Rating Score
Upside/Downside: 122.5% Upside
$425.09 Price Target
Short Interest: Healthy
2.18% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.11
Upright™ Environmental Score
News Sentiment: 0.39
Based on 5 Articles This Week
Insider Trading: Selling Shares
$1.75 M Sold Last Quarter
Proj. Earnings Growth: 28.78%
From $4.10 to $5.28 Per Share

Overall MarketRank^™

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.44 out of 5 stars

Medical Sector

118th out of 1,412 stocks

Analytical Instruments Industry

5th out of 33 stocks

3.2 Analyst's Opinion

Consensus Rating
Illumina has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 3 buy ratings, 6 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $425.09, Illumina has a forecasted upside of 122.5% from its current price of $191.04.
Amount of Analyst Coverage
Illumina has only been the subject of 2 research reports in the past 90 days.

3.0 Short Interest

Percentage of Shares Shorted
2.18% of the outstanding shares of Illumina have been sold short.
Short Interest Ratio / Days to Cover
Illumina has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Illumina has recently increased by 38.87%, indicating that investor sentiment is decreasing significantly.

0.0 Dividend Strength

Dividend Yield
Illumina does not currently pay a dividend.
Dividend Growth
Illumina does not have a long track record of dividend growth.

3.5 Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Illumina has received a 61.69% net impact score from Upright. Illumina seems to create the most significant positive value in categories "Taxes", "Jobs", and "Physical diseases". The positive contribution in the "Physical diseases" impact category is mostly driven by its "Laboratory reagents", "DNA sequencers", and "Laboratory reagents for cells" products. See details.
Environmental Sustainability
The Environmental Impact score for Illumina is -1.11.

1.3 News and Social Media Coverage

News Sentiment
Illumina has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Illumina this week, compared to 9 articles on an average week.
Search Interest
Only 20 people have searched for ILMN on MarketBeat in the last 30 days. This is a decrease of -39% compared to the previous 30 days.
MarketBeat Follows
Only 18 people have added Illumina to their MarketBeat watchlist in the last 30 days. This is a decrease of -57% compared to the previous 30 days.

2.5 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Illumina insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,747,022.00 in company stock.
Percentage Held by Insiders
Only 0.13% of the stock of Illumina is held by insiders.
Percentage Held by Institutions
86.62% of the stock of Illumina is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

3.1 Earnings and Valuation

Earnings Growth
Earnings for Illumina are expected to grow by 28.78% in the coming year, from $4.10 to $5.28 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Illumina is 41.53, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 69.75.
Price to Earnings Ratio vs. Sector
The P/E ratio of Illumina is 41.53, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 77.22.
Price to Earnings Growth Ratio
Illumina has a PEG Ratio of 1.50. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Illumina has a P/B Ratio of 2.78. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

30 days | 90 days | 365 days | Advanced Chart

Receive ILMN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Illumina and its competitors with MarketBeat's FREE daily newsletter.

About Illumina (NASDAQ:ILMN) Stock

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.

June 29, 2022 | benzinga.com

Here's How Much You Would Have Made Owning Illumina Stock In The Last 15 Years - Benzinga - Benzinga

June 28, 2022 | finance.yahoo.com

Illumina Invests in £30M Venture Fund to Advance Breakthroughs in Human Health

June 24, 2022 | finance.yahoo.com

Illumina (ILMN) Gains But Lags Market: What You Should Know

June 22, 2022 | finance.yahoo.com

Illumina Launches Research Test Codeveloped with Merck to Unlock Deeper Insights into the Tumor Genome - Yahoo Finance

June 22, 2022 | seekingalpha.com

Illumina launches research only cancer genomic test co-developed with Merck (NASDAQ:ILMN) - Seeking Alpha

June 21, 2022 | seekingalpha.com

Illumina: Remains Investible Despite The GRAIL Issue

June 20, 2022 | americanbankingnews.com

Illumina, Inc. (NASDAQ:ILMN) Receives $435.92 Consensus Target Price from Brokerages

June 18, 2022 | americanbankingnews.com

Illumina (NASDAQ:ILMN) Reaches New 12-Month Low at $184.04

June 16, 2022 | marketwatch.com

Illumina Inc. stock falls Thursday, still outperforms market - MarketWatch

June 16, 2022 | americanbankingnews.com

Susan H. Tousi Sells 250 Shares of Illumina, Inc. (NASDAQ:ILMN) Stock

June 13, 2022 | barrons.com

Illumina Will Be Fine Despite Recent Concerns, Says CEO - Barron's

June 12, 2022 | americanbankingnews.com

Illumina (NASDAQ:ILMN) Reaches New 12-Month Low at $196.89

June 11, 2022 | nasdaq.com

RSI Alert: Illumina (ILMN) Now Oversold - Nasdaq

June 10, 2022 | fool.com

Why Illumina Stock Is Sinking Today - The Motley Fool

June 10, 2022 | finance.yahoo.com

Why Illumina Stock Is Sinking Today

June 10, 2022 | seekingalpha.com

Illumina names Joydeep Goswami as interim CFO - Seeking Alpha

June 9, 2022 | marketwatch.com

Quest Diagnostics Names Sam Samad CFO, Will Join In July From Illumina - MarketWatch

June 9, 2022 | marketwatch.com

Illumina Says CFO Sam Samad to Depart July 8 - MarketWatch

June 9, 2022 | finance.yahoo.com

JOYDEEP GOSWAMI APPOINTED INTERIM CFO; SAM SAMAD TO DEPART ILLUMINA

June 9, 2022 | finance.yahoo.com

Splendor Illumina! Alchemy Stars Celebrates Its First Anniversary With A New Update - Yahoo Finance

June 8, 2022 | bloomberg.com

Illumina Fights FTC to Keep Its Grail Deal Intact - Bloomberg

June 8, 2022 | finance.yahoo.com

Illumina Announces Next Generation Products and Data at AGBT General Meeting to Advance Innovative Customer Solutions - Yahoo Finance

June 7, 2022 | globenewswire.com

Splendor Illumina! Alchemy Stars Celebrates Its First Anniversary With A New Update - GlobeNewswire

June 7, 2022 | finance.yahoo.com

Do Options Traders Know Something About Illumina (ILMN) Stock We Don't?

June 7, 2022 | finance.yahoo.com

Illumina Announces Next Generation Products and Data at AGBT General Meeting to Advance Innovative Customer Solutions

See More Headlines

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Analytical instruments
Sub-Industry: Life Sciences Tools & Services
Sector: Medical
Current Symbol: NASDAQ:ILMN
CUSIP: 45232710
CIK: 1110803
Web: www.illumina.com
Phone: (858) 202-4500
Fax: 858-202-4766
Employees: 9,150
Year Founded: 1998

Company Calendar

Last Earnings: 5/05/2022
Today: 7/03/2022
Next Earnings (Estimated): 8/04/2022
Fiscal Year End: 12/31/2022

Price Target and Rating

Average Stock Price Forecast: $425.09
High Stock Price Forecast: $520.00
Low Stock Price Forecast: $325.00
Forecasted Upside/Downside: +122.5%
Consensus Rating: Hold
Rating Score (0-4): 2.33333333333333
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): $4.599990
Trailing P/E Ratio: 41.53
Forward P/E Ratio: 46.60
P/E Growth: 1.5
Net Income: $762 million
Net Margins: 15.04%
Pretax Margin: 18.37%
Return on Equity: 8.37%
Return on Assets: 5.78%

Debt

Debt-to-Equity Ratio: 0.11
Current Ratio: 1.85
Quick Ratio: 1.54

Sales & Book Value

Annual Sales: $4.53 billion
Price / Sales: 6.63
Cash Flow: $7.52 per share
Price / Cash Flow: 25.41
Book Value: $68.71 per share
Price / Book: 2.78

Miscellaneous

Outstanding Shares: 157,100,000
Free Float: 156,896,000
Market Cap: $30.01 billion
Optionable: Optionable
Beta: 1.10

Social Links

Illumina Frequently Asked Questions

Should I buy or sell Illumina stock right now?: 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 6 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Illumina stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ILMN, but not buy additional shares or sell existing shares.
View analyst ratings for Illumina or view top-rated stocks.
What is Illumina's stock price forecast for 2022?: 9 brokerages have issued 1-year price objectives for Illumina's shares. Their ILMN stock forecasts range from $325.00 to $520.00. On average, they anticipate Illumina's stock price to reach $425.09 in the next twelve months. This suggests a possible upside of 122.5% from the stock's current price.
View analysts' price targets for Illumina or view top-rated stocks among Wall Street analysts.
How has Illumina's stock price performed in 2022?: Illumina's stock was trading at $380.44 at the beginning of the year. Since then, ILMN stock has decreased by 49.8% and is now trading at $191.04.
View the best growth stocks for 2022 here.
When is Illumina's next earnings date?: Illumina is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Illumina.
How were Illumina's earnings last quarter?: Illumina, Inc. (NASDAQ:ILMN) issued its quarterly earnings data on Thursday, May, 5th. The life sciences company reported $1.07 earnings per share for the quarter, topping analysts' consensus estimates of $0.87 by $0.20. The life sciences company had revenue of $1.22 billion for the quarter, compared to the consensus estimate of $1.22 billion. Illumina had a trailing twelve-month return on equity of 8.37% and a net margin of 15.04%. The business's revenue for the quarter was up 11.9% compared to the same quarter last year. During the same quarter last year, the company posted $1.89 earnings per share.
View Illumina's earnings history.
What guidance has Illumina issued on next quarter's earnings?: Illumina issued an update on its FY 2022 earnings guidance on Monday, May, 23rd. The company provided earnings per share (EPS) guidance of $4.00-$4.20 for the period, compared to the consensus estimate of $4.15. The company issued revenue guidance of $5.16 billion-$5.25 billion, compared to the consensus revenue estimate of $5.23 billion.
Who are Illumina's key executives?: Illumina's management team includes the following people:
Mr. Francis A. deSouza, CEO & Director (Age 51) (LinkedIn Profile)
Mr. Sam A. Samad, Chief Financial Officer (Age 52, Pay $1.06M) (LinkedIn Profile)
Dr. Alexander Aravanis M.D., Ph.D., CTO & Head of Research and Product Devel. (Age 45, Pay $1.05M) (LinkedIn Profile)
Mr. Charles E. Dadswell, Sr. VP, Gen. Counsel & Sec. (Age 63) (LinkedIn Profile)
Ms. Susan H. Tousi, Chief Commercial Officer (Age 53, Pay $1.04M) (LinkedIn Profile)
Stephanie Campos, Pres
Mr. Kevin Carl Pegels, Chief of Global Operations
Mr. Jose A. Torres Jr., Chief Accounting Officer & VP (Age 47)
Ms. Carissa Rollins, Chief Information Officer
Ms. Sallilyn Schwartz, VP of Investor Relations
What is Francis deSouza's approval rating as Illumina's CEO?: 496 employees have rated Illumina CEO Francis deSouza on Glassdoor.com. Francis deSouza has an approval rating of 92% among Illumina's employees. This puts Francis deSouza in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Illumina's key competitors?: Some companies that are related to Illumina include Thermo Fisher Scientific (TMO), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), PerkinElmer (PKI), Bio-Rad Laboratories (BIO), Bio-Techne (TECH), Charles River Laboratories International (CRL), Bruker (BRKR), Pacific Biosciences of California (PACB), Harvard Bioscience (HBIO), aTyr Pharma (LIFE) and BG Medicine (BGMD).
View all of ILMN's competitors.
What other stocks do shareholders of Illumina own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Netflix (NFLX), Walt Disney (DIS), PayPal (PYPL), Salesforce (CRM), Adobe (ADBE), Visa (V) and Micron Technology (MU).
What is Illumina's stock symbol?: Illumina trades on the NASDAQ under the ticker symbol "ILMN."
How do I buy shares of Illumina?: Shares of ILMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Illumina's stock price today?: One share of ILMN stock can currently be purchased for approximately $191.04.
How much money does Illumina make?: Illumina (NASDAQ:ILMN) has a market capitalization of $30.01 billion and generates $4.53 billion in revenue each year. The life sciences company earns $762 million in net income (profit) each year or $4.599990 on an earnings per share basis.
How many employees does Illumina have?: Illumina employs 9,150 workers across the globe.
Does Illumina have any subsidiaries?: The following companies are subsidiares of Illumina: Advanced Liquid Logic Inc., Affomix Corporation, BlueBee, BlueBee Belgium BVBA, BlueBee Holding BV, BlueGnome Ltd, BlueGnome Ltd., Conexio Genomics, Conexio Genomics Pty Ltd., Edico Genome, Edico Genome Corp., Enancio, Enancio SAS, Epicentre Biotechnologies, Epicentre Technologies Corporation, FC Ops Corp., GenoLogics, Grail, Helixis, Illumina (China) Scientific Co Ltd, Illumina AB, Illumina Australia Pty. Ltd., Illumina Belgium BVBA, Illumina Brasil Produtos de Biotecnologia Ltda., Illumina Cambridge Ltd., Illumina Canada Inc., Illumina Canada ULC, Illumina Denmark ApS, Illumina Finland Oy, Illumina France Holding Sarl, Illumina France Sarl, Illumina GmbH, Illumina Hong Kong Limited, Illumina Iceland ehf, Illumina India Biotechnology Private Limited, Illumina Ireland Commercial Limited, Illumina Italy S.r.l., Illumina K.K. Japan, Illumina Korea Ltd., Illumina Netherlands B.V., Illumina New Zealand Limited, Illumina Norway AS, Illumina Productos de Espana S.L.U., Illumina Rus, Illumina Rus LLC, Illumina Shanghai (Trading) Co Ltd, Illumina Shanghai (Trading) Co Ltd Beijing Branch, Illumina Shanghai (Trading) Co. Ltd., Illumina Singapore Pte. Ltd., Illumina Software Inc., Illumina Switzerland GmbH, Illumina US Manufacturing Operations Inc., Liquid Logic, Moleculo, NextBio, Solexa, Verinata Health, Verinata Health Inc., and thromboDx BV.
Read More
When was Illumina founded?: Illumina was founded in 1998.
How can I contact Illumina?: Illumina's mailing address is 200 ILLUMINA WAY, SAN DIEGO CA, 92122. The official website for Illumina is www.illumina.com. The life sciences company can be reached via phone at (858) 202-4500, via email at ir@illumina.com, or via fax at 858-202-4766.

This page (NASDAQ:ILMN) was last updated on 7/3/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Illumina Stock Forecast, Price & News

Illumina MarketRank™ Forecast

Overall MarketRank™

3.2 Analyst's Opinion

3.0 Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

0.0 Dividend Strength

3.5 Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

1.3 News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

2.5 Company Ownership

3.1 Earnings and Valuation

Receive ILMN Stock News and Ratings via Email

About Illumina (NASDAQ:ILMN) Stock

ILMN Stock News Headlines

Industry, Sector and Symbol

Company Calendar

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Illumina Frequently Asked Questions

Should I buy or sell Illumina stock right now?

What is Illumina's stock price forecast for 2022?

How has Illumina's stock price performed in 2022?

When is Illumina's next earnings date?

How were Illumina's earnings last quarter?

What guidance has Illumina issued on next quarter's earnings?

Who are Illumina's key executives?

What is Francis deSouza's approval rating as Illumina's CEO?

Who are some of Illumina's key competitors?

What other stocks do shareholders of Illumina own?

What is Illumina's stock symbol?

How do I buy shares of Illumina?

What is Illumina's stock price today?

How much money does Illumina make?

How many employees does Illumina have?

Does Illumina have any subsidiaries?

When was Illumina founded?

How can I contact Illumina?

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™